Addition of durvalumab and CTLA-4 inhibitor tremelimumab to gemcitabine/cisplatin in first-line therapy in CCA patients was investigated in a single-center phase II study.241 Group A, comprising 32 patients received chemotherapy followed by chemotherapy plus durvalumab and tremelimumab. The gene discussed is CTLA4; the disease is cholangiocarcinoma.